Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

There is a lack of effective predictive biomarkers to precisely assign optimal therapy to cancer patients. While most efforts are directed at inferring drug response phenotype based on genotype, there is very focused and useful phenotypic information to be gained from directly perturbing the patient's living cancer cell with the drug(s) in question. To satisfy this unmet need, we developed the Dynamic BH3 Profiling technique to measure early changes in net pro-apoptotic signaling at the mitochondrion ("priming") induced by chemotherapeutic agents in cancer cells, not requiring prolonged ex vivo culture. We find in cell line and clinical experiments that early drug-induced death signaling measured by Dynamic BH3 Profiling predicts chemotherapy response across many cancer types and many agents, including combinations of chemotherapies. We propose that Dynamic BH3 Profiling can be used as a broadly applicable predictive biomarker to predict cytotoxic response of cancers to chemotherapeutics in vivo.

[1]  Benjamin Haibe-Kains,et al.  Inconsistency in large pharmacogenomic studies , 2013, Nature.

[2]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[3]  P. Jänne,et al.  Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor , 2010, Oncogene.

[4]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.

[5]  S. Digumarthy,et al.  BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. , 2011, Cancer discovery.

[6]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[7]  A. Letai,et al.  Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes , 2010, Proceedings of the National Academy of Sciences.

[8]  A. Letai,et al.  BH3 profiling in whole cells by fluorimeter or FACS. , 2013, Methods.

[9]  W. Alexander,et al.  American Society of Clinical Oncology , 2020, Definitions.

[10]  C. Sawyers The cancer biomarker problem , 2008, Nature.

[11]  Peter Sorger,et al.  BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. , 2013, Molecular cell.

[12]  Michael B Yaffe,et al.  The Scientific Drunk and the Lamppost: Massive Sequencing Efforts in Cancer Discovery and Treatment , 2013, Science Signaling.

[13]  S. Korsmeyer,et al.  Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death , 2001, Science.

[14]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[15]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[16]  Levi A Garraway,et al.  Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. , 2012, Cancer discovery.

[17]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[18]  R. Gale,et al.  Chronic myeloid leukemia. , 1992, The American journal of medicine.

[19]  D. Dittmer,et al.  Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. , 2010, Blood.

[20]  Levi A Garraway,et al.  Circumventing cancer drug resistance in the era of personalized medicine. , 2012, Cancer discovery.

[21]  Gordon B Mills,et al.  Functional proteomic profiling of AML predicts response and survival. , 2009, Blood.

[22]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[23]  Kwok-Kin Wong,et al.  Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition , 2009, Proceedings of the National Academy of Sciences.

[24]  D. Green,et al.  The BCL-2 family reunion. , 2010, Molecular cell.

[25]  A. Letai,et al.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. , 2007, Cancer cell.

[26]  A. Letai,et al.  Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML , 2012, Cell.

[27]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[28]  John R. Engen,et al.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.

[29]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[30]  Visualizing the Landscape of Selection Biomarkers in Current Phase III Oncology Clinical Trials , 2010, Science Translational Medicine.

[31]  K. Flaherty,et al.  Elucidating distinct roles for NF1 in melanomagenesis. , 2013, Cancer discovery.

[32]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[33]  S. Korsmeyer,et al.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. , 2002, Cancer cell.

[34]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[35]  M. Somerfield,et al.  American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Letai,et al.  Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. , 2007, Cancer research.